FiercePharma3h
GSK, Sanofi, CSL nab $72M in BARDA funding to boost bird flu vaccine supply
CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...
FiercePharma4h
US' top IV fluid maker Baxter voices uncertainty about recovery timeline at North Carolina facility hit by Helene
After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter ...
FiercePharma6h
American Society for Meningitis Prevention paints the town purple and blue for World Meningitis Day
A nonprofit dedicated to improving vaccination rates to eradicate meningococcal meningitis is brightening things up this ...
FiercePharma6h
BeiGene launches PD-1 drug Tevimbra at 10% discount to Merck's Keytruda
BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...
FiercePharma7h
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...
FiercePharma8h
Breaking down BIOSECURE—Industry implications and what comes next
Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculate | This ...
FiercePharma8h
Fierce Pharma Asia—Roche's $850M-plus deal with Regor; Legend's busy week; WuXi asset sales?
On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American ...
FiercePharma10h
After winning historic nod, Zevra CCO expects new drug Miplyffa to become 'cornerstone' of Niemann-Pick treatment
Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C ...